Literature DB >> 17462753

Effect of statins on contrast-induced nephropathy in patients with acute myocardial infarction treated with primary angioplasty.

Jing-Lin Zhao, Yue-Jin Yang, Yuan-hui Zhang, Shi-Jie You, Yong-Jian Wu, Run-Lin Gao.   

Abstract

We investigated whether pretreatment with statin may prevent contrast-induced nephropathy in patients who underwent primary coronary intervention for acute myocardial infarction (AMI). A total of 279 consecutive patients who underwent successful primary angioplasty for a first AMI were studied. Contrast-induced nephropathy was defined as an increase in serum creatinine of > or =5 mg/dL after the primary PCI. 56 patients receiving statin treatment before admission had lower incidence of the contrast-induced nephropathy than those without it (7.1% and 20.6%, P<0.01). Multivariable logistic regression analysis revealed that absence of statin pre-treatment was a significant predictor of the reperfusion arrhythmia along with anterior AMI, baseline creatinine value, time-to-reperfusion, higher volume of the contrast agent. Pre-treatment with statin could reduce the contrast-induced nephropathy after primary coronary intervention in patients with AMI.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17462753     DOI: 10.1016/j.ijcard.2007.01.123

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  9 in total

1.  Acute kidney injury based on the KDIGO criteria among ST elevation myocardial infarction patients treated by primary percutaneous intervention.

Authors:  Gilad Margolis; Amir Gal-Oz; Sevan Letourneau-Shesaf; Shafik Khoury; Gad Keren; Yacov Shacham
Journal:  J Nephrol       Date:  2017-11-28       Impact factor: 3.902

2.  Prognostic Implications of Acute Renal Impairment among ST Elevation Myocardial Infarction Patients with Preserved Left Ventricular Function.

Authors:  Yacov Shacham; Amir Gal-Oz; Jeremy Ben-Shoshan; Gad Keren; Yaron Arbel
Journal:  Cardiorenal Med       Date:  2016-02-03       Impact factor: 2.041

3.  Statin treatment before percutaneous cononary intervention.

Authors:  Mario Leoncini; Anna Toso; Mauro Maioli; Francesco Tropeano; Francesco Bellandi
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

4.  Renal impairment according to acute kidney injury network criteria among ST elevation myocardial infarction patients undergoing primary percutaneous intervention: a retrospective observational study.

Authors:  Yacov Shacham; Eran Leshem-Rubinow; Arie Steinvil; Eyal Ben Assa; Gad Keren; Arie Roth; Yaron Arbel
Journal:  Clin Res Cardiol       Date:  2014-02-13       Impact factor: 5.460

5.  The role of statins in the prevention of contrast induced nephropathy: a meta-analysis of 8 randomized trials.

Authors:  Lucia Barbieri; Monica Verdoia; Alon Schaffer; Matteo Nardin; Paolo Marino; Giuseppe De Luca
Journal:  J Thromb Thrombolysis       Date:  2014-11       Impact factor: 2.300

Review 6.  Efficacy of atorvastatin on the prevention of contrast-induced acute kidney injury: a meta-analysis.

Authors:  Ling-Yun Liu; Yang Liu; Mei-Yan Wu; Yan-Yan Sun; Fu-Zhe Ma
Journal:  Drug Des Devel Ther       Date:  2018-03-02       Impact factor: 4.162

7.  Atorvastatin attenuates experimental contrast-induced acute kidney injury: a role for TLR4/MyD88 signaling pathway.

Authors:  Rongzheng Yue; Chuan Zuo; Jing Zeng; Baihai Su; Ye Tao; Songmin Huang; Rui Zeng
Journal:  Ren Fail       Date:  2017-11       Impact factor: 2.606

8.  Neutrophil gelatinase-associated lipocalin (NGAL) for the prediction of acute kidney injury in chronic kidney disease patients treated with primary percutaneous coronary intervention.

Authors:  Ariel Banai; Keren-Lee Rozenfeld; Dana Levit; Ilan Merdler; Itamar Loewenstein; Shmuel Banai; Yacov Shacham
Journal:  Int J Cardiol Heart Vasc       Date:  2020-12-17

9.  Contrast induced nephropathy in urology.

Authors:  Viji Samuel Thomson; Kumar Narayanan; J Chandra Singh
Journal:  Indian J Urol       Date:  2009 Oct-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.